Unity Biotechnology, Inc. (UBX): Price and Financial Metrics

Unity Biotechnology, Inc. (UBX): $1.96

0.03 (+1.55%)

POWR Rating

Component Grades








Add UBX to Watchlist
Sign Up

Industry: Biotech




#52 of 345

in industry

UBX Price/Volume Stats

Current price $1.96 52-week high $5.72
Prev. close $1.93 52-week low $1.46
Day low $1.92 Volume 10,582
Day high $1.97 Avg. volume 222,028
50-day MA $1.94 Dividend yield N/A
200-day MA $2.64 Market Cap 28.66M

UBX Stock Price Chart Interactive Chart >

Unity Biotechnology, Inc. (UBX) Company Bio

Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company’s lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is based in Brisbane, California.

UBX Latest News Stream

Event/Time News Detail
Loading, please wait...

UBX Latest Social Stream

Loading social stream, please wait...

View Full UBX Social Stream

Latest UBX News From Around the Web

Below are the latest news stories about UNITY BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate UBX as an investment opportunity.

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | November 16, 2023

UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2023. “Following positive efficacy and safety data at 48 weeks from a single injection of UBX1325 (foselutoclax) in patients with diabetic macular edema, we are working to quickly and efficiently advance UBX1325 (foseluto

Yahoo | November 13, 2023

UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,143,000 shares of common stock, having an exercise price of $8.50 per share, issued by UNITY on August 22, 2022, at a reduced e

Yahoo | November 10, 2023

Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks

Here are the best longevity stocks to consider.

Matthew Farley on InvestorPlace | October 17, 2023

20 Foods Consumed By Longest Living People Every Day

In this article, we will be taking a look at the 20 foods consumed by longest living people every day. If you are not interested in the details about market insights on longevity, head straight to the 5 Foods Consumed By Longest Living People Every Day. The pursuit of longevity and vitality has captivated humankind […]

Yahoo | October 4, 2023

Read More 'UBX' Stories Here

UBX Price Returns

1-mo -4.85%
3-mo -22.22%
6-mo -44.63%
1-year -33.11%
3-year -96.74%
5-year -98.57%
YTD -28.47%
2022 -81.23%
2021 -72.14%
2020 -27.32%
2019 -55.66%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!